Article

DME implant gets UK OK

The United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for 190 µm fluocinolone acetonide intravitreal implant in applicator (Iluvien, Alimera Sciences) for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

Atlanta-The United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for 190 µm fluocinolone acetonide intravitreal implant in applicator (Iluvien, Alimera Sciences) for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

This marketing authorization follows the completion of the decentralized regulatory procedure in the European Union (EU), in which the MHRA, serving as the “reference member state,” delivered a positive outcome for the fluocinolone acetonide implant along with six “concerned members states”: Austria, France, Germany, Italy, Spain, and Portugal. The UK authorization is the second national approval in the EU, preceded by the approval by Austria. The company expects to receive additional national marketing authorizations in the coming months.

“As the global impact of diabetes expands, there is an increasing need for innovative treatments such as [fluocinolone]. We are pleased to receive marketing authorization from our reference member state and are targeting to make this long-term therapy available to the many DME patients there by the end of this year,” said Dan Myers, president and chief executive officer of Alimera Sciences.

The sustained-release intravitreal implant delivers sub-microgram levels of fluocinolone acetonide for up to 36 months.

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.